Literature DB >> 19641369

Multigene methylation analysis of conventional renal cell carcinoma.

H Onay1, S Pehlivan, M Koyuncuoglu, Z Kirkali, F Ozkinay.   

Abstract

Renal cell carcinoma (RCC) is the most common malignancy of the kidney. Since RCC is curable when it is confined to the renal capsule, early diagnosis is extremely important. Promoter hypermethylation is the most common mechanism for the inactivation of the tumor suppressor genes (TSG) in the development of human cancer. This study aimed to investigate the methylation profiles of 7 TSG (RASSF1A, ECAD, TIMP3, APC, MGMT, p16 and RARbeta2) in 3 different tissue samples (normal, premalign, malign) of patients with RCC. Twenty-one patients diagnosed with RCC were included in the study. Methylation-specific polymerase chain reaction was performed to detect the methylation patterns of the 7 TSG. High methylation rates for the genes RASSF1A (76%), p16 (80%), ECAD (42%), TIMP3 (33%) and MGMT (33%) were observed in the patients with RCC. The APC (14%) and RARbeta2 (19%) genes showed low methylation rates. In conclusion, 5 TSG (RASSF1A, ECAD, TIMP3, MGMT and p16) showed high methylation rates in RCC patients. A methylation-based gene test including these genes may be useful in the early detection of RCC. Copyright 2009 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2009        PMID: 19641369     DOI: 10.1159/000224878

Source DB:  PubMed          Journal:  Urol Int        ISSN: 0042-1138            Impact factor:   2.089


  11 in total

1.  DNA Methylation and Flavonoids in Genitourinary Cancers.

Authors:  Neelam Mukherjee; Addanki P Kumar; Rita Ghosh
Journal:  Curr Pharmacol Rep       Date:  2015-04-01

Review 2.  Genetic and epigenetic alterations during renal carcinogenesis.

Authors:  Eri Arai; Yae Kanai
Journal:  Int J Clin Exp Pathol       Date:  2010-12-13

3.  Reduced expression of Slit2 in renal cell carcinoma.

Authors:  Wei-Jie Ma; Yu Zhou; Dan Lu; Dong Dong; Xiao-Jun Tian; Jie-Xi Wen; Jun Zhang
Journal:  Med Oncol       Date:  2013-11-15       Impact factor: 3.064

Review 4.  The Role of Epigenetics in the Progression of Clear Cell Renal Cell Carcinoma and the Basis for Future Epigenetic Treatments.

Authors:  Javier C Angulo; Claudia Manini; Jose I López; Angel Pueyo; Begoña Colás; Santiago Ropero
Journal:  Cancers (Basel)       Date:  2021-04-25       Impact factor: 6.639

5.  Alterations of the WNT7A gene in clear cell renal cell carcinomas.

Authors:  Aleksandr G Kondratov; Sergiy M Kvasha; Liubov A Stoliar; Alina M Romanenko; Yury M Zgonnyk; Vasily V Gordiyuk; Elena V Kashuba; Alla V Rynditch; Eugene R Zabarovsky; Vladimir I Kashuba
Journal:  PLoS One       Date:  2012-10-08       Impact factor: 3.240

6.  Epigenetics of renal cell carcinoma: the path towards new diagnostics and therapeutics.

Authors:  Mark R Morris; Eamonn R Maher
Journal:  Genome Med       Date:  2010-09-03       Impact factor: 11.117

7.  Hypermethylation of the 16q23.1 tumor suppressor gene ADAMTS18 in clear cell renal cell carcinoma.

Authors:  Ben Xu; Lian Zhang; Cheng Luo; Yan Qi; Yun Cui; Jian-Ming Ying; Qian Zhang; Jie Jin
Journal:  Int J Mol Sci       Date:  2015-01-05       Impact factor: 5.923

Review 8.  Quantitative assessment of the relationship between RASSF1A gene promoter methylation and bladder cancer (PRISMA).

Authors:  Leyun Zhan; Bingyi Zhang; Yaojun Tan; Chengliang Yang; Chenhong Huang; Qiongya Wu; Yulin Zhang; Xiaobo Chen; Mi Zhou; Aihua Shu
Journal:  Medicine (Baltimore)       Date:  2017-02       Impact factor: 1.889

9.  Decreased expression of RASSF1A tumor suppressor gene is associated with worse prognosis in clear cell renal cell carcinoma.

Authors:  Jakub Klacz; Piotr M Wierzbicki; Agata Wronska; Agnieszka Rybarczyk; Marcin Stanislawowski; Tomasz Slebioda; Agata Olejniczak; Marcin Matuszewski; Zbigniew Kmiec
Journal:  Int J Oncol       Date:  2015-11-18       Impact factor: 5.650

10.  Clinical significance of p16INK4A and p14ARF promoter methylation in renal cell carcinoma: a meta-analysis.

Authors:  Yu Ren; Li Xiao; Guobin Weng; Bingyi Shi
Journal:  Oncotarget       Date:  2017-06-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.